Bicara Therapeutics Inc.

XNASHealth care

Last traded price · USD

$8.75

−1.57%Delayed · Pre-market

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 18:24 IST · A quote does not mean the product is available to trade on your account.

Day's open: —
Previous close: $8.89
Volume: 877
Day's high: —
Day's low: —

In brief

Bicara Therapeutics Inc. is a health care company listed on Nasdaq, valued at about $579M.
Its shares closed at $8.89 on 4 Nov 2026, down 39.7% over the past year.
From India you can buy BCAX in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy Bicara Therapeutics Inc. (BCAX) shares from India?

Yes. Indian residents can invest in the US stock market under the Reserve Bank of India's Liberalised Remittance Scheme (LRS), which lets a resident individual remit up to USD 250,000 per financial year, across all permitted purposes combined. US-listed stocks and ETFs are a permitted investment under the LRS. You are solely responsible for ensuring your remittances comply with the LRS annual limit, the applicable Tax Collected at Source (TCS) rules, and all reporting requirements, including Schedule FA in your income-tax return.

Do I need the price of a whole BCAX share to invest?

Yes. You can buy fractional shares, which lets you invest a fixed rupee/dollar amount even in high-priced stocks. For example, if one share trades at USD 1,000 and you invest USD 100, you receive 0.1 of a share.

How much can I invest in US stocks in a year?

Under the LRS, an Indian resident can remit up to USD 250,000 per financial year (April to March) across all permitted purposes combined, from their own funds. This is a per-individual limit set by the RBI.

Can I trade BCAX options or futures?

No. Under RBI / FEMA rules, the LRS does not permit margin trading or speculative instruments such as futures, options, or other derivatives. Your US account is a cash account, not a derivatives and margin account.

Insights

Quotes run fifteen minutes behind.

Behind SPY and its sector fund XLV over 1 year
1 month: −46.3% (SPY −1.6%, XLV +13.5%). 3 months: −65.7% (SPY −0.4%, XLV +15.5%). 1 year: −39.7% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: BCAX, SPY and XLV · as of 4 Nov 2026
13.0% above its 52-week low
Closed at $8.89 on 4 Nov 2026: 71.3% below the 52-week high of $30.99 (7 Jul 2026) and 13.0% above the low of $7.87 (2 Nov 2026).
Daily price bars, split-adjusted · as of 4 Nov 2026
Below its 50- and 200-day averages
The 4 Nov 2026 close of $8.89 was 52.7% below its 50-day average ($18.81) and 57.8% below its 200-day average ($21.09). It has closed below the 200-day for 31 sessions, since 23 Sep 2026. The 50-day average crossed below the 200-day on 21 Oct 2026, 10 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
11.5 days to cover short interest
10.3M shares were sold short at the 15 Oct 2026 settlement, 15.6% of the 66.2M shares outstanding; covering them would take 11.5 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
RSI(14) at 22.4, 30 or below
The 14-session relative strength index closed at 22.4 on 4 Nov 2026, its 6th session at 30 or below. By convention a reading of 30 or below is called oversold and 70 or above overbought.
Daily closes, split-adjusted; Wilder's 14-session RSI · as of 4 Nov 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month−46.3%

6 months−62.6%

1 year−39.7%

5 years—

Newswire

About

Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b. The company's goal is to build a fully integrated, commercial-stage biopharmaceutical company that develops important therapies for people living with cancer, starting with ficerafusp alfa.

Website

Notable moves

October 28, 2026
−44.16%
September 29, 2025
+18.45%
May 23, 2025
−40.80%

Bicara Therapeutics Inc.

XNASHealth care

Last traded price · USD

$8.75

−1.57%Delayed · Pre-market

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 18:24 IST · A quote does not mean the product is available to trade on your account.

Day's open: —
Previous close: $8.89
Volume: 877
Day's high: —
Day's low: —

In brief

Bicara Therapeutics Inc. is a health care company listed on Nasdaq, valued at about $579M.
Its shares closed at $8.89 on 4 Nov 2026, down 39.7% over the past year.
From India you can buy BCAX in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy Bicara Therapeutics Inc. (BCAX) shares from India?

Do I need the price of a whole BCAX share to invest?

How much can I invest in US stocks in a year?

Can I trade BCAX options or futures?

Insights

Quotes run fifteen minutes behind.

Behind SPY and its sector fund XLV over 1 year
1 month: −46.3% (SPY −1.6%, XLV +13.5%). 3 months: −65.7% (SPY −0.4%, XLV +15.5%). 1 year: −39.7% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: BCAX, SPY and XLV · as of 4 Nov 2026
13.0% above its 52-week low
Closed at $8.89 on 4 Nov 2026: 71.3% below the 52-week high of $30.99 (7 Jul 2026) and 13.0% above the low of $7.87 (2 Nov 2026).
Daily price bars, split-adjusted · as of 4 Nov 2026
Below its 50- and 200-day averages
The 4 Nov 2026 close of $8.89 was 52.7% below its 50-day average ($18.81) and 57.8% below its 200-day average ($21.09). It has closed below the 200-day for 31 sessions, since 23 Sep 2026. The 50-day average crossed below the 200-day on 21 Oct 2026, 10 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
11.5 days to cover short interest
10.3M shares were sold short at the 15 Oct 2026 settlement, 15.6% of the 66.2M shares outstanding; covering them would take 11.5 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
RSI(14) at 22.4, 30 or below
The 14-session relative strength index closed at 22.4 on 4 Nov 2026, its 6th session at 30 or below. By convention a reading of 30 or below is called oversold and 70 or above overbought.
Daily closes, split-adjusted; Wilder's 14-session RSI · as of 4 Nov 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month−46.3%

6 months−62.6%

1 year−39.7%

5 years—

Newswire

About

Website

Notable moves

October 28, 2026
−44.16%
September 29, 2025
+18.45%
May 23, 2025
−40.80%

Bicara Therapeutics Inc.

Bicara Therapeutics Inc. in brief

Behind SPY and its sector fund XLV over 1 year

13.0% above its 52-week low

Below its 50- and 200-day averages

11.5 days to cover short interest

RSI(14) at 22.4, 30 or below

Bicara Therapeutics Inc.

Bicara Therapeutics Inc. in brief

Behind SPY and its sector fund XLV over 1 year

13.0% above its 52-week low

Below its 50- and 200-day averages

11.5 days to cover short interest

RSI(14) at 22.4, 30 or below